Dx Dialogues: exciting upcoming developments in the treatment of CKD

Nephrologist Sean Hashmi, MD, discusses EOS789 and the early data for pan-phosphate approaches in the treatment of CKD and hyperphosphatemia.

Transcript

00:00

The EOS789 is important molecule because it's going to block multiple pathways at the same time.

00:09

And so blocking PiT-1, PiT-2, and it blocks the NaPi2b pathway.

00:16

This is really important because now you're talking about a molecule that does multiple pathways simultaneously.

00:23

By doing this pan approach, you're actually able to prevent any of the upregulation phosphorus

00:30

absorption that ends up occurring. So you're hitting all of the phosphorus pathways for absorption all at the same time.

00:37

There's some very preliminary evidence around this, and the evidence is actually quite exciting. So what we end up seeing is not only that there's

00:45

a reduction in phosphorus. There's also a reduction in FGF23. There's a reduction in PTH, which

00:52

we need to balance with cardiovascular risk as well along with bone health. And you also find you're reducing the risk

01:00

of aortic calcification. There's only about a phase 1B study so far, and what they've been able to show is using this approach,

01:08

there weren't any serious adverse events. It was very well tolerated, and you are seeing significant results in terms